Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older, or children aged 2 to 17 years old
- People diagnosed with a type of blood cancer called precursor B-cell acute lymphoblastic leukemia (B-ALL), with more than 5% cancer cells found in the bone marrow
- People with B-ALL that does not involve a genetic change called the Philadelphia chromosome (Ph-negative), AND whose cancer meets at least one of these conditions: the cancer did not go into remission after the first round of treatment; the cancer did not go into remission after a second round of treatment; the cancer came back within 12 months of first going into remission; the cancer has relapsed a second time or more; or the cancer came back after a bone marrow/stem cell transplant from a donor
- People with B-ALL that does involve the Philadelphia chromosome (Ph-positive), who have already received two or more targeted medicines called tyrosine kinase inhibitors (TKIs) and whose cancer meets the relapse or treatment-failure conditions listed above — or people with a specific genetic mutation called T315I (confirm with trial site)
Who may not be able to join:
- People who have a history of a related blood cancer called Burkitt's leukemia
- People who received a treatment targeting a protein called CD19 within the past 3 months
- People who had a donor stem cell or bone marrow transplant within the past 12 weeks
- People who previously received a type of cell therapy called CAR-T cell treatment within the past 3 months
- People who have a significant history of, or current, brain or nervous system disease
- People who have had cancer spread to the brain or the membranes surrounding the brain, or whose cancer in the brain is not currently controlled
- People with a history of immune system deficiency, including anyone who has previously tested positive for HIV
- People with a history of serious heart or blood vessel disease affecting the heart or brain
- People who have an active autoimmune disease (where the immune system attacks the body) that may flare up
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jianxiang Wang, Dr., Institute of Hematology & Blood Diseases Hospital, China
Phone: 1-888-577-8839
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Dose Escalation Phase: Number of Participants who Experience at Least One Adverse Event (AE); Dose Escalation Phase: Number of Participants who Discontinue Study Treatment Due to an AE; Dose Escalation Phase: Number of Participants Who Experience a Dose-limiting Toxicity (DLT); Dose Escalation Phase: Maximum Tolerated Dose (MTD) of MK-1045; Phase II: Complete Remission (CR) Rate
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.